Crossmark

Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression

Published Online: 2020-01-22

Published Print: 2020-09

Authors

Wang, B.

Wang, F.

Ding, A.

Zhao, H.

Bu, X. https://orcid.org/0000-0001-8750-1171
License Information

Text and Data Mining valid from 2020-01-22

Version of Record valid from 2020-01-22
More Information

Article History

Received: 11 December 2019

Accepted: 26 December 2019

First Online: 22 January 2020

Compliance with ethical standards

:

: The authors declare no conflict of interest.

: The study was approved by the Ethics Committee of Jinan Infectious Disease Hospital Affiliated to Shandong University.

: Informed consent was obtained from all individual participants included in this study.

Document is current